When Head and Neck Cancer Returns After Full Dose Radiation

When head and neck cancer recurs after a full course of chemoradiation, the dose already delivered to surrounding healthy tissue severely limits what can safely be given again. The spinal cord, salivary glands, and mucosal lining have cumulative tolerance thresholds. Exceeding them risks serious, sometimes irreversible, toxicity.

In these situations, a multidisciplinary specialist review can identify options that may not have been considered at the initial treating centre. This includes salvage surgery where anatomy permits, carefully planned re-irradiation with modern techniques, particle therapy at centres with relevant experience, and, at the few facilities offering it, boron neutron capture therapy (BNCT). The goal is not to advocate for any single modality but to lay out every realistic path so the clinical team and the patient can make an informed decision.

Published data on BNCT for recurrent head and neck squamous cell carcinoma show a meaningful signal. Kankaanranta et al. (IJROBP, 2012) reported a 45% complete response rate. Koivunoro et al. (Radiother Oncol. 137, 2019) documented 53% overall survival at 2 years, against 14% after stereotactic radiotherapy (Vargo et al., IJROBP 100, 2018). These results come from centres in Finland and Japan with dedicated BNCT infrastructure.

It is important to note that BNCT is available today only at specific centres in Japan and Finland. Access depends on clinical eligibility, centre capacity, and in some cases regulatory approval status. BNCT is one option among several advanced approaches, not a universal solution.

Early specialist consultation provides more options than waiting until the case is urgent. When recurrence is detected early, the range of feasible interventions is wider, surgical margins may be more favourable, and the patient is in better condition to tolerate treatment.